In Vitro Metabolism of Certain Nornuciferine Derivatives

Smith, Robert V.; Sood, S

doi:10.1002/jps.2600601113

Cited by 21 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These compounds were identified by their physical and spectroscopic properties and by comparison with published data (Smith and Sood, 1971;Achenbach and Schwinn, 1995;Hu et al, 2010). Fig.…”

Section: Chemical Analysis Of Tamentioning

confidence: 99%

Antidepressant-like effects of an alkaloid extract of the aerial parts of Annona cherimolia in mice

Martínez‐Vázquez

Estrada-Reyes

Escalona

et al. 2012

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Section: Chemical Analysis Of Tamentioning

confidence: 99%

Antidepressant-like effects of an alkaloid extract of the aerial parts of Annona cherimolia in mice

Martínez‐Vázquez

Estrada-Reyes

Escalona

et al. 2012

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…In rats, the major part of apomorphine undergoes hepatic metabolism by O ‐glucuronidation and is then eliminated as glucuronides in the urine 20, 21. However, in vitro studies suggest that apomorphine may also be methylated by the enzyme COMT,22–25 largely present in the liver, with production of 10 methoxy‐apomorphine or apocodeine 26. A recent study has shown that tolcapone, a central and peripheral COMT inhibitor, can increase the apomorphine bioavailability by reducing its liver catabolism in Sprague–Dawley rats 27.…”

Section: Discussionmentioning

confidence: 99%

Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study

Zijlmans

Debilly²,

Rascol

et al. 2004

Movement Disorders

View full text Add to dashboard Cite

We investigated whether administration of the catechol-O-methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamics and safety of entacapone and apomorphine coadministration in these patients were examined. The study followed a three-sequence, three-period, crossover design. Patients were randomly assigned to one of three sequences that included single oral doses of entacapone 200 mg, entacapone 400 mg, and placebo in a predefined order. On 3 separate test days, study treatment was administered before apomorphine. The study evaluations (pharmacokinetics, tapping test, and dyskinesia evaluation [Abnormal Involuntary Movements Scale - AIMS]) were performed on these days. Furthermore, Unified Parkinson Disease Rating Scale (UPDRS) scores were evaluated at baseline and study end. Pharmacokinetic parameters for apomorphine (C(max), AUC, t(max), t(1/2)) were unchanged by the administration of entacapone, and changes in both the tapping test and AIMS score were similar with all treatments (entacapone 200 mg, entacapone 400 mg, and placebo). There was no significant difference in mean total UPDRS scores between baseline and study end. The administration of entacapone did not change the pharmacokinetic or pharmacodynamic effects of apomorphine in these patients or prolong the clinical effect of apomorphine. Thus, apomorphine may be safely administered to patients receiving therapy with levodopa and entacapone, providing a useful addition to treatment for patients with advanced Parkinson's disease.

show abstract

“…Nomuciferine derivatives administered intraperitoneally to mice as hydrobromide or hydrochloride provoked intense clonic convulsions. Rat, rabbit, and guinea pig liver micro somes also dealkylated N-alkylated analog of nomuciferine [28]. N-Propylnomuciferine was the most effective convulsant agent [27].…”

Section: Pharmacologymentioning

confidence: 99%